These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26057711)

  • 1. Against the clock towards new Ebola virus therapies.
    Martínez-Romero C; García-Sastre A
    Virus Res; 2015 Nov; 209():4-10. PubMed ID: 26057711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases.
    Tully CM; Lambe T; Gilbert SC; Hill AV
    Lancet Infect Dis; 2015 Mar; 15(3):356-9. PubMed ID: 25595637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ebola : an uncontrolled outbreak despite vaccines and new treatments].
    Vetter P; Kaiser L
    Rev Med Suisse; 2020 Apr; 16(690):739-743. PubMed ID: 32301308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Therapeutic Approaches Against Ebola Virus Infection.
    Soni M; Tulsian K; Barot P; Vyas VK
    Recent Adv Antiinfect Drug Discov; 2024; 19(4):276-299. PubMed ID: 38279760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Review on Ebola (EBOV) Virus: Future Prospects.
    Khan S; Muhammad ; Rauf A; Khan A; Rizwan M; Patel S; Khan H; Mahasneh AM; Mubarak MS
    Infect Disord Drug Targets; 2018; 18(2):96-104. PubMed ID: 28820067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?
    Meyer M; Malherbe DC; Bukreyev A
    Trends Microbiol; 2019 Jan; 27(1):8-16. PubMed ID: 30201511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent Advances in Vaccines and Drugs Against the Ebola Virus].
    Zhu X; Yao C; Wei Y; Kou Z; Hu K
    Bing Du Xue Bao; 2015 May; 31(3):287-92. PubMed ID: 26470536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ebola virus vaccines: an overview of current approaches.
    Marzi A; Feldmann H
    Expert Rev Vaccines; 2014 Apr; 13(4):521-31. PubMed ID: 24575870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ebola Virus: Pathogenesis and Countermeasure Development.
    Furuyama W; Marzi A
    Annu Rev Virol; 2019 Sep; 6(1):435-458. PubMed ID: 31567063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ebola: Lessons on Vaccine Development.
    Feldmann H; Feldmann F; Marzi A
    Annu Rev Microbiol; 2018 Sep; 72():423-446. PubMed ID: 30200851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms.
    O'Donnell K; Marzi A
    Expert Rev Vaccines; 2020 Mar; 19(3):267-277. PubMed ID: 32129120
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of ebola virus disease.
    Kilgore PE; Grabenstein JD; Salim AM; Rybak M
    Pharmacotherapy; 2015 Jan; 35(1):43-53. PubMed ID: 25630412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ebola vaccine and treatment].
    Takada A
    Uirusu; 2015; 65(1):61-70. PubMed ID: 26923959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ebola Virus Transmission Caused by Persistently Infected Survivors of the 2014-2016 Outbreak in West Africa.
    Subissi L; Keita M; Mesfin S; Rezza G; Diallo B; Van Gucht S; Musa EO; Yoti Z; Keita S; Djingarey MH; Diallo AB; Fall IS
    J Infect Dis; 2018 Nov; 218(suppl_5):S287-S291. PubMed ID: 29920602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alisporivir Has Limited Antiviral Effects Against Ebola Virus Strains Makona and Mayinga.
    Chiramel AI; Banadyga L; Dougherty JD; Falzarano D; Martellaro C; Brees D; Taylor RT; Ebihara H; Best SM
    J Infect Dis; 2016 Oct; 214(suppl 3):S355-S359. PubMed ID: 27511894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Strategies against Ebola Virus Infection.
    Liu CH; Hu YT; Wong SH; Lin LT
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral therapeutics for the treatment of Ebola virus infection.
    Cardile AP; Downey LG; Wiseman PD; Warren TK; Bavari S
    Curr Opin Pharmacol; 2016 Oct; 30():138-143. PubMed ID: 27639220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmission, Human Population, and Pathogenicity: the Ebola Case in Point.
    Delgado R; Simón F
    Microbiol Spectr; 2018 Mar; 6(2):. PubMed ID: 29573259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ebola virus disease candidate vaccines under evaluation in clinical trials.
    Martins KA; Jahrling PB; Bavari S; Kuhn JH
    Expert Rev Vaccines; 2016 Sep; 15(9):1101-12. PubMed ID: 27160784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.